Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ondansetron Clear all
Completed Phase 3 Interventional Results available

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

NCT00601172
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant, Dexamethasone, Placebo, Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 23, 2026, 7:17 PM EDT
Terminated Phase 2 Interventional

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

NCT04226170
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
DAS-001
Drug
Lead sponsor
DAS-MG, Inc
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

NCT02991456
View directory record Official record
Conditions
Chemo-radiation Induced Nausea and Vomiting
Interventions
Rolapitant, Ondansetron
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery

NCT00659945
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Aprepitant plus Ondansetron, Ondansetron plus placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
BEKINDA, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 23, 2026, 7:17 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Ondansetron Use for Preventing Pruritus in Patients Undergoing Cesarean Section

NCT06297499
View directory record Official record
Conditions
Pruritus Caused by Drug
Interventions
Ondansetron 8mg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

Ondansetron Treatment for Alcoholism

NCT00000443
View directory record Official record
Conditions
Alcoholism
Interventions
ondansetron (Zofran)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
25 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

NCT01450826
View directory record Official record
Conditions
Nausea, Vomiting, Glioma
Interventions
aprepitant, ondansetron
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

NCT00366834
View directory record Official record
Conditions
Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
86
States / cities
Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 3 Interventional Results available

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

NCT02246439
View directory record Official record
Conditions
Gastroenteritis, Gastritis
Interventions
RHB-102, Placebo Oral Tablet
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
12 Years to 85 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
26
States / cities
Bakersfield, California • Sacramento, California • Sylmar, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

NCT00006348
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Nausea and Vomiting, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
ondansetron, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
12
States / cities
Scottsdale, Arizona • Urbana, Illinois • Des Moines, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Results available

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

NCT02760069
View directory record Official record
Conditions
Nausea
Interventions
Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

NCT07103720
View directory record Official record
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

NCT00934180
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Zofran®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

NCT00108095
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
intravenous ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Montgomery, Alabama • Phoenix, Arizona • Arcadia, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional

Ondansetron for the Treatment of Methamphetamine Dependence - 1

NCT00040053
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
6
States / cities
Chula Vista, California • Costa Mesa, California • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 4 Interventional

Uncomplicated Nausea and Vomiting in the Emergency Department

NCT00778011
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Ondansetron, Metoclopramide
Drug
Lead sponsor
WellSpan Health
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 23, 2026, 7:17 PM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

NCT01572012
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron, Ondansetron + Hylenex, Zofran ODT, Ondansetron solution
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
19 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2014 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

NCT00437229
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant (GW679769) Oral Tablets, dexamethasone, ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

NCT01801475
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

NCT03973047
View directory record Official record
Conditions
Nausea
Interventions
Bremelanotide, Zofran, Placebo
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 23, 2026, 7:17 PM EDT
Completed Phase 2 Interventional Results available

Ondansetron, Alcohol Use, and Alcohol-Related Symptoms In HIV+ Persons

NCT01254877
View directory record Official record
Conditions
Alcohol Abuse, Alcohol Dependence
Interventions
Ondansetron, placebo ondansetron
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 23, 2026, 7:17 PM EDT
Withdrawn Not applicable Interventional

Aprepitant PO vs Ondansetron IV for Prevention of Postoperative Nausea and Vomiting

NCT00699894
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
aprepitant 40 mg, ondansetron 4 mg
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 25 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 23, 2026, 7:17 PM EDT